Evidence map›Paper›PMID 42453418›Full record

ArticleActa pharmaceutica Sinica. B2026

Acquired pharmacoresistance in temporal lobe epilepsy is driven by Na

Yuanzhi Yang, Menghan Li, Minjuan Sun, Shuo Zhang, Xiongfeng Guo, Shuangshuang Wu, Yiwei Gong, Lan Huang, Tong Liu, Junxiu Ye and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yuanzhi YangZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Menghan LiZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Minjuan SunZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Shuo ZhangZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Xiongfeng GuoZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Shuangshuang WuZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Yiwei GongZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Lan HuangZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Tong LiuZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Junxiu YeZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Xiangyu MaZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Xiaoyun QiuZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Shuang WangEpilepsy Center, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310050, China.
Fan FeiZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Yu DuZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Yi WangZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Zhong ChenZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Cenglin XuZhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacoresistance to anti-seizure medications (ASMs) remains a major unmet challenge in temporal lobe epilepsy (TLE), and occurs diversely, as classified to primary or acquired manner. The pathophysiological underpinnings of acquired pharmacoresistance remain elusive. Here, using a hippocampal kindling mouse model, we established that prolonged lamotrigine (LTG) treatment-either during or after kindling-induces broad-spectrum resistance to multiple ASMs, effectively recapitulating clinical patterns of acquired pharmacoresistance. Multimodal interrogation revealed hyperexcitability of subicular pyramidal neurons as a critical factor in pharmacoresistance, characterized by elevated c-Fos expression specifically within the subiculum, as well as hyperexcitability of subicular glutamatergic pyramidal neurons. This hyperexcitability phenotype stemmed from Na

Indexed as

Anti-seizure medicationHyperexcitabilityNav1.6PharmacoresistancePyramidal neuronsSodium channelSubiculumTemporal lobe epilepsy

Identifiers

PMID42453418
PMCPMC13366238

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.